Review Article | Open Access
Ravi Philip Rajkumar, "Prolactin and Psychopathology in Schizophrenia: A Literature Review and Reappraisal", Schizophrenia Research and Treatment, vol. 2014, Article ID 175360, 12 pages, 2014. https://doi.org/10.1155/2014/175360
Prolactin and Psychopathology in Schizophrenia: A Literature Review and Reappraisal
Secretion of the anterior pituitary hormone prolactin can be significantly increased by antipsychotic drugs, leading to a range of adverse effects in patients with schizophrenia. However, there is evidence from a variety of studies that prolactin may also be related to symptom profile and treatment response in these patients, and recent work has identified variations in prolactin secretion even in drug-free patients. In this paper, a selective review of all relevant studies pertaining to prolactin and schizophrenia, including challenge and provocation studies, is presented. The implications of this work are discussed critically. A tentative model, which synthesizes these findings and argues for a significant role for prolactin in the development of schizophrenia, is outlined.
Prolactin is a polypeptide hormone secreted by the anterior pituitary gland. Prolactin has multiple functions, including lactation and maternal-infant bonding, in mammals. Recent work has found it to be relevant to parental and sexual behaviour in humans [1, 2] as well. Various factors, including gender, sexual activity, childbirth, stress, smoking, and drugs, can affect the release of prolactin [3, 4].
The production of prolactin is inhibited by dopamine release in the hypothalamo-pituitary circuit and can be increased by blocking type 2 (D2) dopamine receptors. Most available antipsychotic drugs can therefore cause elevations in prolactin secretion. This increase is associated with a variety of adverse effects: lack of libido and erectile dysfunction in men , amenorrhoea and galactorrhoea in women , acceleration of osteoporosis in women , weight gain , and—potentially—an increased risk of cancer, particularly breast cancer in women . The association of prolactin with male sexual dysfunction is complex and has been challenged by some authors  but is supported by research showing that antipsychotics which cause greater elevations in prolactin also have more marked sexual adverse effects . Besides this, a variety of studies over the past four decades have examined other facets of the relationship between prolactin and schizophrenia and call for a reappraisal of this relationship. In this paper, the author highlights the important findings pertaining to prolactin and schizophrenia, excluding the literature on drug-induced hyperprolactinemia which has been extensively reviewed elsewhere. The author also proposes a model that may explain these findings. In the discussion that follows, the term “prolactin levels” refers to plasma prolactin, unless otherwise specified.
2. Studies of Prolactin Levels in Drug-Naïve Patients
As antipsychotic treatment generally causes hyperprolactinemia, measuring prolactin levels in drug-naïve patients is a useful method of assessing their relationship with schizophrenia itself. These studies are summarized in Table 1.
As seen from Table 1, the results of these studies are equivocal and are confounded by various methodological issues, including sampling time, gender, the use of medications, and the form of prolactin being assayed (total plasma, bioactive, or CSF). The two most recent studies to be published both found elevated plasma prolactin in drug-naïve patients with first-episode psychosis, while older studies found lower or equivalent levels.
3. Studies Reporting Relationships between Prolactin and Symptom Profile
The next question to be considered is whether elevated prolactin is related to specific symptoms or dimensions of schizophrenia, which is a multidimensional entity. Results of these studies are described in Table 2.
Examining the above studies yields a clearer, though not unequivocal, picture: there is a fairly consistent and negative association between plasma prolactin and surrogate measures of positive symptoms—such as specific delusions or the paranoid subtype of schizophrenia. Segal et al.  have interpreted these results in terms of increased dopaminergic tone in patients with paranoid symptoms, which is consistent with the dopamine hypothesis of schizophrenia. However, our interpretation remains confounded by the presence of studies with negative findings and by the variations in methodology adopted by different authors—particularly in terms of patient gender and the measures used to assess symptom dimensions.
4. Challenge and Provocative Test-Based Studies
Given the inconsistent results of studies measuring basal plasma prolactin, another fruitful line of enquiry would be assessing the prolactin response to various external stimuli in patients with schizophrenia, as these would give us a clearer notion of the physiological processes implicated in the altered levels. A variety of drugs—hormones, adrenergic agonists, serotonergic agonists, and dopamine antagonists—have been used to study prolactin release in patients with schizophrenia. The results of these studies are outlined in Table 3.
|Study uses an agent that inhibits prolactin release.|
Some consistent findings emerge across these studies. A blunted prolactin response to pharmacological challenge in schizophrenia is documented across various classes of agents—adrenergic , serotonergic [14, 15], and dopaminergic [16–20]. However, these results are confounded by variables such as the dose of the pharmacological challenge, the effects of treatment, age and gender, and the duration of psychosis, and negative or inverse results have also been reported. With reference to drugs that inhibit prolactin release, results are more consistent, with many studies reporting a reduced suppression in patients [21–23]. Only one study has examined the effects of stress in this patient population and found a significantly greater increase in stress-stimulated prolactin in schizophrenia .
Relations with specific symptom dimensions have not been found consistently across studies. Positive correlations have been reported between the prolactin response to a serotonergic challenge and negative symptoms  as well as affective symptoms  and between prolactin release after TRH administration and thought disorder . Negative correlations have been reported between prolactin response and inattention  as well as the severity of delusions . Blunted prolactin responses have been associated with a “Kraepelinian” diagnosis of schizophrenia  and with schizophreniform disorder  in particular. A greater prolactin response to fenfluramine was associated with treatment resistance in one study . Incidentally, one study found an association between a lower basal prolactin and positive symptoms , which is consistent with the results of Segal’s studies [12, 32].
The interpretation of these findings is complicated by the wide range of potential mechanisms involved. The blunting of the prolactin response to dopamine antagonists [16–18] may indicate dopamine receptor supersensitivity, while the worsening of positive symptoms  associated with a blunted response to serotonergic challenge may implicate reduced serotonin receptor sensitivity in these symptoms. In contrast, the exaggerated prolactin response to serotonin in resistant schizophrenia is indicative of serotonergic hyperfunction; this is consistent with the fact that clozapine, an antagonist at multiple serotonin receptors, is the treatment of choice in this population.
5. Studies Reporting Relationships between Prolactin and Treatment Response
As prolactin elevation is related to D2 receptor blockade, prolactin may be a useful surrogate marker of the blockade achieved and thereby—in an indirect manner—of the efficacy of antipsychotic medications. Studies that have focused on this association are summarized in Table 4.
The results of the above studies suggest that there is a clear relationship between changes in prolactin level and the response to certain antipsychotics, with the best evidence pertaining to risperidone. The equivocal results obtained with other drugs may be related to the observation that prolactin has little predictive value beyond a certain “plateau” level  and may also reflect variables such as the effects of gender , the use of drugs with low dopamine antagonist activity , short treatment durations , small sample sizes [36–40], and the use of high doses of depot antipsychotics . The suggestions that challenge tests can be used to assess the serotonergic effects of clozapine  and that plasma prolactin can be used to estimate therapeutic doses of dopamine antagonists  are both intriguing but require replication. Of note, some of the most relevant positive results have been obtained in male patients [33, 42, 43], suggesting that the utility of prolactin as a biomarker of drug response may be gender-specific.
6. Studies Reporting Relationships between Prolactin and Tardive Dyskinesia
As tardive dyskinesia (TD) is linked to dopamine receptor supersensitivity , alterations in prolactin levels would be expected in these patients. This relationship has been examined by a small number of studies, listed in Table 5.
Because of the small sample sizes involved, the results of these studies must be interpreted with caution. They may indicate dopamine receptor supersensitivity  or GABA receptor dysfunction , but variables such as gender, duration of illness, the nature of medications used, and the study design (basal prolactin versus challenge tests) must also be taken into account. With the available evidence, the association between prolactin and TD seems slight at best.
7. Studies Linking Prolactin with Circadian Rhythms
Alterations in genes regulating circadian rhythm have been linked to both schizophrenia and the affective disorders . Like other hormones, prolactin shows circadian variations in its rhythm and may be used to track circadian rhythm changes in schizophrenia. These studies are summarized in Table 6.
These studies suggest that there are clear alterations in the circadian rhythm of prolactin in schizophrenia, particularly with regard to sleep [48, 49]. The possibility that schizophrenia has a unique circadian profile of prolactin and sleep changes, distinct from those seen in depression , must be seriously considered but requires further replication in larger samples using a consistent study protocol.
8. Prolactin and Suicide
Suicide attempts and completed suicide are not uncommon in schizophrenia . A link between the prolactin response to a serotonergic challenge and affective symptoms, such as depression and guilt, has been reported in one study ; given this, it is logical to examine the association between prolactin levels and suicide. In a study examining 439 patients, 118 of whom were diagnosed as having psychosis, Pompili et al.  found slightly reduced prolactin levels in those patients who had attempted suicide.
9. Genetic Studies of Prolactin in Schizophrenia
Two recent studies have examined genetic variants in prolactin in patients with schizophrenia. Rybakowski et al.  examined the frequency of the −1149 G/T functional polymorphism of the prolactin gene in 403 patients, compared to 653 healthy controls. They found that the G allele was significantly more common in patients, particularly in males, and pointed out that this variation was similar to that reported in autoimmune diseases. Souza et al.  examined the association between the prolactin and prolactin receptor (PRLR) genes and both tardive dyskinesia and treatment response but failed to find a significant association in either case.
10. Summary and Hypothesis
The literature reviewed above, though complex, suggests fruitful lines for further enquiry. First, the association between raised prolactin and acute episodes of schizophrenia needs to be replicated in larger samples. Riecher-Rössler et al.  provide an intriguing explanation for this finding. They suggest that stress leads to an increased level of prolactin, which triggers dopamine release by a feedback mechanism; this increase in dopamine transmission may mediate the link between stress and psychosis. There are several lacunae in this hypothesis: (1) neither of the two studies cited above has measured stress or recent life events; (2) while raised prolactin may increase dopamine activity in the tuberoinfundibular pathway, it is not known if it can produce similar changes in the mesolimbic pathway; (3) this proposal fails to explain why several studies found lower or normal prolactin levels. Despite this, the hypothesis merits further testing, as well as extension to conditions such as acute and transient psychosis, where the role of stress is much clearer. The finding that patients with schizophrenia have an exaggerated prolactin response to stress may be relevant here.
Second, the association of lower prolactin levels with positive symptoms and “paranoid” symptoms in particular are in line with the revised dopamine hypothesis of schizophrenia. This association can certainly be interpreted as suggesting increased dopamine transmission in this subgroup, with the same caveat as above: we do not know how well prolactin correlates with dopamine activity in the mesolimbic pathway. If this finding can be replicated, it provides some support for the notion of subtypes within the broad category of schizophrenia. Given that the most recent edition of the DSM has consciously omitted the traditional subtypes , a biomarker for a paranoid subtype could lead to a reversion of this change.
Third, provocation studies provide further support for the idea of blunted or lowered prolactin secretion in patients with “positive” schizophrenia. Whether this relationship holds good for other conditions in which “positive” symptoms are prominent—such as psychotic mood disorders or acute and transient psychosis—needs to be decided by further research. Though alterations in dopamine, serotonin, and GABA activity are all hinted at by individual provocation studies, the true nature of these abnormalities is likely to be slight and subtle, and their significance is unclear. A similar conclusion would apply to the results of studies of circadian rhythm.
Fourth, the association between prolactin and treatment response to antipsychotics, as well as its relationship to tardive dyskinesia, is inconsistent and, in the latter case, unlikely to be of much clinical significance. Given the numerous confounders that can affect prolactin levels, the inconsistency of positive findings and the negative results of recent genetic research, it is unlikely that a consistent association can be made. Changes in prolactin level may be a more sensitive indicator of response in some cases, though these probably reach a plateau at higher doses and may depend crucially on the drug being studied.
Finally, the association of prolactin gene variants with schizophrenia—though preliminary—suggests that there is more to the schizophrenia-prolactin association than simple dopamine-based models. Though Rybakowski et al.  invoked the possibility of an autoimmune mechanism, another possibility exists: genetic variations in prolactin are a genuine risk factor for psychosis. As authors writing in other contexts have pointed out, prolactin has a bewildering array of effects on the behaviour of mammals, but its exact behavioural effects in humans are unknown . Given its relationship with parental bonding, an effect of prolactin on social cognition and behavior—both of which are significantly impaired in schizophrenia—is plausible. A tentative model could run as follows. First, genetic variations in prolactin lead to an exaggerated prolactin response to stress, which may further be modulated by childhood adversity or possibly by substance abuse [56, 57]. This is supported by the results of recent research which has found elevated prolactin levels not only in first-episode psychosis, but in over 25% of patients with “at-risk” or prodromal psychosis ; the authors of this paper have also suggested, in line with the above model, that this could reflect a stress response. Second, when exposed to further stressors, increases in prolactin levels may indirectly—as in Riecher-Rossler’s proposal of a feedback increase in dopamine, which may also be exaggerated—lead to some of the symptoms of psychosis. Third, as a result of subsequent changes, which again may include increased dopamine transmission, prolactin levels decline, and lower prolactin levels may correlate with the development of positive symptoms, such as delusions. This is consistent with both the possibility that prolactin influences social behaviour, and the finding that some forms of stress, such as childhood neglect  and social defeat , can sensitize the mesolimbic dopamine pathway. Fourth, a moderate increase in prolactin, brought about by antipsychotics, may play a role in alleviating the positive symptoms of schizophrenia. A role for higher cortical centres in modulating prolactin release, which would be consistent with the above, is suggested by the results of studies of lobotomized patients. This hypothesis complements the dopamine model of schizophrenia and is consistent with most of the evidence reviewed above. Further research into the genetic links between prolactin and schizophrenia, the exact relationship between prolactin and central dopamine, the significance of circadian changes in prolactin, and the effects of prolactin on human social behaviour will provide a true test of this proposal.
A review of the literature on prolactin and schizophrenia suggests that the relationship between them is complex and not confined to the adverse effects of antipsychotics. Though the above interpretations must be regarded as imperfect and tentative, they do call for a reappraisal of the role of prolactin in the various stages of schizophrenia, particularly with regard to its onset and to the development of positive symptoms. Research in this area may lead to an improved understanding of schizophrenia, as well as a better delineation of the effects of prolactin on social behaviour and cognition in humans.
Conflict of Interests
The author declares that there is no conflict of interests regarding the publication of this paper.
- I. Gordon, O. Zagoory-Sharon, J. F. Leckman, and R. Feldman, “Prolactin, Oxytocin, and the development of paternal behavior across the first six months of fatherhood,” Hormones and Behavior, vol. 58, no. 3, pp. 513–518, 2010.
- T. H. C. Kruger, B. Leeners, E. Naegeli et al., “Prolactin secretory rhythm in women: immediate and long-term alterations after sexual contact,” Human Reproduction, vol. 27, no. 4, pp. 1139–1143, 2012.
- S. Ranabir and K. Reetu, “Stress and hormones,” Indian Journal of Endocrinology and Metabolism, vol. 15, pp. 18–22, 2011.
- C. Ohta, N. Yasui-Furukori, H. Furukori et al., “The effect of smoking status on the plasma concentration of prolactin already elevated by risperidone treatment in schizophrenia patients,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 35, no. 2, pp. 573–576, 2011.
- M. Baggaley, “Sexual dysfunction in schizophrenia: focus on recent evidence,” Human Psychopharmacology, vol. 23, no. 3, pp. 201–209, 2008.
- P. M. Haddad and A. Wieck, “Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management,” Drugs, vol. 64, no. 20, pp. 2291–2314, 2004.
- V. O'Keane, “Antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment of schizophrenia,” Journal of Psychopharmacology, vol. 22, no. 2, supplement, pp. 70–75, 2008.
- T. Baptista, A. Lacruz, T. Meza et al., “Antipsychotic drugs and obesity: is prolactin involved?” Canadian Journal of Psychiatry, vol. 46, no. 9, pp. 829–834, 2001.
- J. R. Bostwick, S. K. Guthrie, and V. L. Ellingrod, “Antipsychotic-induced hyperprolactinemia,” Pharmacotherapy, vol. 29, no. 1, pp. 64–73, 2009.
- M. van Bruggen, T. van Amelsvoort, L. Wouters, P. Dingemans, L. de Haan, and D. Linszen, “Sexual dysfunction and hormonal changes in first episode psychosis patients on olanzapine or risperidone,” Psychoneuroendocrinology, vol. 34, no. 7, pp. 989–995, 2009.
- J. Bobes, M. P. García-Portilla, J. Rejas et al., “Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE study,” Journal of Sex and Marital Therapy, vol. 29, no. 2, pp. 125–147, 2003.
- M. Segal, A. Avital, S. Berstein, A. Derevenski, S. Sandbank, and A. Weizman, “Prolactin and estradiol serum levels in unmedicated male paranoid schizophrenia patients,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 31, no. 2, pp. 378–382, 2007.
- M.-C. Mokrani, F. Duval, T. S. Diep, P. E. Bailey, and J. P. MacHer, “Multihormonal responses to clonidine in patients with affective and psychotic symptoms,” Psychoneuroendocrinology, vol. 25, no. 7, pp. 741–752, 2000.
- B. Lerer, A. Ran, M. Blacker et al., “Neuroendocrine responses in chronic schizophrenia. Evidence for serotonergic dysfunction,” Schizophrenia Research, vol. 1, no. 6, pp. 405–410, 1988.
- N. Iqbal, G. M. Asnis, S. Wetzler, R. S. Kahn, S. R. Kay, and H. M. Van Praag, “The MCPP challenge test in schizophrenia: hormonal and behaviral responses,” Biological Psychiatry, vol. 30, no. 8, pp. 770–778, 1991.
- N. A. Keks, D. L. Copolov, J. Kulkarni et al., “Basal and haloperidol-stimulated prolactin in neuroleptic-free men with schizophrenia defined by 11 diagnostic systems,” Biological Psychiatry, vol. 27, no. 11, pp. 1203–1215, 1990.
- N. A. Keks, D. P. McKenzie, L. H. Low et al., “Multidiagnostic evaluation of prolactin response to haloperidol challenge in schizophrenia: maximal blunting in Kraepelinian patients,” Biological Psychiatry, vol. 32, no. 5, pp. 426–437, 1992.
- D. L. Copolov, N. A. Keks, J. Kulkarni et al., “Prolactin response to low-dose haloperidol challenge in schizophrenic, non-schizophrenic psychotic, and control subjects,” Psychoneuroendocrinology, vol. 15, no. 3, pp. 225–231, 1990.
- N. A. Keks, D. L. Copolov, and B. S. Singh, “Abnormal prolactin response to haloperidol challenge in men with schizophrenia,” The American Journal of Psychiatry, vol. 144, no. 10, pp. 1335–1337, 1987.
- D. Nerozzi, A. Magnani, V. Sforza et al., “Plasma prolactin response to domperidone in acute schizophrenia and schizophreniform illness,” Psychiatry Research, vol. 34, no. 2, pp. 139–147, 1990.
- P. Monteleone, G. Zontini, and L. Steardo, “Failure of the gabaergic drug, sodium valproate, to reduce basal plasma prolactin secretion in chronic schizophrenia,” Psychoneuroendocrinology, vol. 10, no. 4, pp. 475–480, 1985.
- M. Scheinin, E. K. Syvälahti, J. Hietala et al., “Effects of apomorphine on blood levels of homovanillic acid, growth hormone and prolactin in medicated schizophrenics and healthy control subjects,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 9, no. 4, pp. 441–449, 1985.
- J. Rotrosen, B. Angrist, C. Clark, S. Gershon, F. S. Halpers, and E. J. Sachar, “Suppression of prolactin in dopamine agonists in schizophrenics and controls,” The American Journal of Psychiatry, vol. 135, no. 8, pp. 949–951, 1978.
- K. Tsuchiya, “Studies on prolactin in major psychoses—with reference to prolactin response to stress in schizophrenia,” Folia Psychiatrica et Neurologica Japonica, vol. 38, no. 1, pp. 53–56, 1984.
- R. P. Sharma, V. Singh, P. G. Janicak, J. I. Javaid, and G. N. Pandey, “The prolactin response to fenfluramine in schizophrenia is associated with negative symptoms,” Schizophrenia Research, vol. 39, no. 1, pp. 85–89, 1999.
- K. M. Abel, V. O'Keane, and R. M. Murray, “Enhancement of the prolactin response to d-fenfluramine in drug-naive schizophrenic patients,” British Journal of Psychiatry, vol. 168, pp. 57–60, 1996.
- J. Spoov, P.-E. Bredbacka, B. Appelberg et al., “Prolactin response to submaximal stimulation by TRH in nonaffective psychoses,” Biological Psychiatry, vol. 29, no. 3, pp. 204–210, 1991.
- J. Spoov, P.-E. Bredbacka, and U.-H. Stenman, “An abnormal relation between basal prolactin levels and prolactin response to 12.5 microg TRH i.v. in drug-naïve patients with first-episode schizophrenia,” Schizophrenia Research, vol. 119, no. 1–3, pp. 41–46, 2010.
- J. Kulkarni, N. A. Keks, G. Stuart et al., “Relationship of psychotic symptoms to haloperidol-stimulated prolactin release,” Acta Psychiatrica Scandinavica, vol. 82, no. 4, pp. 271–274, 1990.
- P. Monteleone, A. Tortorella, R. Borriello, P. Cassandro, and M. Maj, “Prolactin hyperresponsiveness to D-fenfluramine in drug-free schizophrenic patients: a placebo-controlled study,” Biological Psychiatry, vol. 45, no. 12, pp. 1606–1611, 1999.
- I. N. Ferrier, E. C. Johnstone, and T. J. Crow, “Hormonal effects of apomorphine in schizophrenia,” British Journal of Psychiatry, vol. 144, no. 4, pp. 349–357, 1984.
- M. Segal, A. Avital, M. Rojas et al., “Serum prolactin levels in unmedicated first-episode and recurrent schizophrenia patients: a possible marker for the disease's subtypes,” Psychiatry Research, vol. 127, no. 3, pp. 227–235, 2004.
- T. Van Putten, S. R. Marder, and J. Mintz, “Serum prolactin as a correlate of clinical response to haloperidol,” Journal of Clinical Psychopharmacology, vol. 11, no. 6, pp. 357–361, 1991.
- L. Wang, L. Yu, A.-P. Zhang et al., “Serum prolactin levels, plasma risperidone levels, polymorphism of cytochrome P450 2D6 and clinical response in patients with schizophrenia,” Journal of Psychopharmacology, vol. 21, no. 8, pp. 837–842, 2007.
- J. Volavka, P. Czobor, T. B. Cooper et al., “Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol,” Journal of Clinical Psychiatry, vol. 65, no. 1, pp. 57–61, 2004.
- H. Y. Meltzer, D. A. Busch, and V. S. Fang, “Serum neuroleptic and prolactin levels in schizophrenic patients and clinical response,” Psychiatry Research, vol. 9, no. 4, pp. 271–283, 1983.
- R. Rimon, R. Kampman, R. Laru-Sompa, and L. Heikkila, “Serum and cerebrospinal fluid prolactin patterns during neuroleptic treatment in schizophrenic patients,” Pharmacopsychiatry, vol. 18, no. 3, pp. 252–254, 1985.
- G. Meco, M. Casacchia, M. Attenni, A. Iafrate, F. Castellana, and U. Ecari, “Haloperidol decanoate in schizophreniform disorders. Clinical and neuroendocrine aspects,” Acta Psychiatrica Belgica, vol. 83, no. 1, pp. 57–68, 1983.
- A. Jørgensen , J. Andersen, N. Bjørndal, S. J. Dencker, L. Lundin, and U. Malm, “Serum concentrations of cis(Z)-flupentixol and prolactin in chronic schizophrenic patients treated with flupentixol and cis(Z)-flupentixol decanoate,” Psychopharmacology, vol. 77, no. 1, pp. 58–65, 1982.
- T. Kolakowska, M. Orr, M. Gelder, M. Heggie, D. Wiles, and M. Franklin, “Clinical significance of plasma drug and prolactin levels during acute chlorpromazine treatment: a replication study,” British Journal of Psychiatry, vol. 135, no. 10, pp. 352–359, 1979.
- H. Jones, V. A. Curtis, P. Wright, and J. V. Lucey, “Neuroendocrine evidence that clozapine's serotonergic antagonism is relevant to its efficacy in treating hallucinations and other positive schizophrenic symptoms,” The American Journal of Psychiatry, vol. 155, no. 6, pp. 838–840, 1998.
- X. Y. Zhang, D. F. Zhou, C. L. Yuan, P. Y. Zhang, G. Y. Wu, and Y. C. Shen, “Risperidone-induced increase in serum prolactin is correlated with positive symptom improvement in chronic schizophrenia,” Psychiatry Research, vol. 109, no. 3, pp. 297–302, 2002.
- A. G. Awad, Y. D. Lapierre, K.-G. Jostell et al., “Selective dopamine D2 antagonist and prolactin response in acute schizophrenia—results from remoxipride studies. The Canadian Remoxipride Study Group,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 14, no. 5, pp. 769–777, 1990.
- H. C. Margolese, G. Chouinard, T. T. Kolivakis, L. Beauclair, and R. Miller, “Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 1: pathophysiology and mechanisms of induction,” Canadian Journal of Psychiatry, vol. 50, no. 9, pp. 541–547, 2005.
- J.-C. Shim, Y.-H. Kim, D. L. Kelly, J.-G. Lee, and R. R. Conley, “Tardive dyskinesia predicts prolactin response to buspirone challenge in people with schizophrenia,” Journal of Neuropsychiatry and Clinical Neurosciences, vol. 17, no. 2, pp. 221–226, 2005.
- P. Monteleone, M. Maj, M. G. Ariano, M. Iovino, L. Fiorenza, and L. Steardo, “Prolactin response to sodium valproate in schizophrenics with and without tardive dyskinesia,” Psychopharmacology, vol. 96, no. 2, pp. 223–226, 1988.
- H. A. Mansour, M. E. Talkowski, J. Wood et al., “Association study of 21 circadian genes with bipolar I disorder, schizoaffective disorder and schizophrenia,” Bipolar Disorders, vol. 11, pp. 701–710, 2009.
- E. Van Cauter, P. Linkowski, M. Kerkhofs et al., “Circadian and sleep-related endocrine rhythms in schizophrenia,” Archives of General Psychiatry, vol. 48, no. 4, pp. 348–356, 1991.
- B. Appelberg, H. Katila, and R. Rimón, “REM sleep and prolactin in patients with non-affective psychoses,” Psychoneuroendocrinology, vol. 27, no. 6, pp. 661–669, 2002.
- B. A. Palmer, V. S. Pankratz, and J. M. Bostwick, “The lifetime risk of suicide in schizophrenia: a reexamination,” Archives of General Psychiatry, vol. 62, no. 3, pp. 247–253, 2005.
- M. Pompili, S. Gibiino, M. Innamorati et al., “Prolactin and thyroid hormone levels are associated with suicide attempts in psychiatric patients,” Psychiatry Research, vol. 200, pp. 389–394, 2012.
- J. K. Rybakowski, M. Dmitrzak-Weglarz, P. Kapelski, and J. Hauser, “Functional -1149 G/T polymorphism of the prolactin gene in schizophrenia,” Neuropsychobiology, vol. 65, no. 1, pp. 41–44, 2011.
- R. P. Souza, H. Y. Meltzer, J. A. Lieberman, A. N. Voineskos, G. Remington, and J. L. Kennedy, “Prolactin as a biomarker for treatment response and tardive dyskinesia in schizophrenia subjects: old thoughts revisited from a genetic perspective,” Human Psychopharmacology, vol. 26, no. 1, pp. 21–27, 2011.
- A. Riecher-Rössler, J. K. Rybakowski, M. O. Pflueger et al., “Hyperprolactinemia in antipsychotic-naive patients with first-episode psychosis.,” Psychological Medicine, vol. 43, no. 12, pp. 2571–2582, 2013.
- R. Tandon and W. T. Carpenter Jr., “DSM-5 status of psychotic disorders: 1 year prepublication,” Schizophrenia Bulletin, vol. 38, no. 3, pp. 369–370, 2012.
- J. Kaufman, B. Birmaher, J. Perel et al., “Serotonergic functioning in depressed abused children: clinical and familial correlates,” Biological Psychiatry, vol. 44, no. 10, pp. 973–981, 1998.
- G. Gerra, C. Leonardi, E. Cortese et al., “Childhood neglect and parental care perception in cocaine addicts: relation with psychiatric symptoms and biological correlates,” Neuroscience and Biobehavioral Reviews, vol. 33, no. 4, pp. 601–610, 2009.
- J. Aston, E. Rechsteiner, N. Bull, S. Borgwardt, U. Gschwandtner, and A. Riecher-Rössler, “Hyperprolactinaemia in early psychosis-not only due to antipsychotics,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 34, no. 7, pp. 1342–1344, 2010.
- J. C. Pruessner, F. Champagne, M. J. Meaney, and A. Dagher, “Dopamine release in response to a psychological stress in humans and its relationship to early life maternal care: a positron emission tomography study using [11C] raclopride,” Journal of Neuroscience, vol. 24, no. 11, pp. 2825–2831, 2004.
- J.-P. Selten and E. Cantor-Graae, “Hypothesis: social defeat is a risk factor for schizophrenia?” British Journal of Psychiatry, vol. 191, no. 51, pp. s9–s12, 2007.
- C. Garcia-Rizo, E. Fernandez-Egea, C. Oliveira et al., “Prolactin concentrations in newly diagnosed, antipsychotic-naïve patients with nonaffective psychosis,” Schizophrenia Research, vol. 134, no. 1, pp. 16–19, 2012.
- M. D. Warner, A. M. Walker, D. C. D'Souza, D. Lee, D. Nasseri, and C. A. Peabody, “Lower prolactin bioactivity in unmedicated schizophrenic patients,” Psychiatry Research, vol. 102, no. 3, pp. 249–254, 2001.
- M. L. Rao, G. Gross, and G. Huber, “Altered interrelationship of dopamine, prolactin, thyrotropin and thyroid hormone in schizophrenic patients,” European Archives of Psychiatry and Neurological Sciences, vol. 234, no. 1, pp. 8–12, 1984.
- A. Kuruvilla, G. Srikrishna, J. Peedicayil, K. Kuruvilla, and A. S. Kanagasabapathy, “A study on serum prolactin levels in schizophrenia: correlation with positive and negative symptoms,” International Clinical Psychopharmacology, vol. 8, no. 3, pp. 177–179, 1993.
- D. Muck-Seler, N. Pivac, M. Mustapic, Z. Crncevic, M. Jakovljevic, and M. Sagud, “Platelet serotonin and plasma prolactin and cortisol in healthy, depressed and schizophrenic women,” Psychiatry Research, vol. 127, no. 3, pp. 217–226, 2004.
- R. Rimon, J. Luera, R. Kampman, and M. Hyyppa, “Prolactin levels in cerebrospinal fluid of patients with chronic schizophrenia,” Neuropsychobiology, vol. 7, no. 2, pp. 87–93, 1981.
- M. T. Hyyppä, J. Liira, R. Kampman, and R. Rimon, “Low prolactin levels in cerebrospinal fluid: an aftereffect of lobotomy in chronic schizophrenia,” Acta Psychiatrica Belgica, vol. 80, no. 4, pp. 452–457, 1980.
- M. Segal, A. Avital, A. Derevenski, S. Berstein, S. Sandbank, and A. Weizman, “Prolactin serum levels in paranoid versus nonparanoid male schizophrenia patients treated with risperidone,” International Clinical Psychopharmacology, vol. 22, no. 4, pp. 192–196, 2007.
- K. Otani, T. Kondo, M. Ishida et al., “Plasma prolactin concentration and psychopathology of schizophrenia,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 20, pp. 1369–1374, 1996.
- J. W. Newcomer, S. J. Riney, S. Vinogradov, and J. G. Csernansky, “Plasma prolactin and homovanillic acid as markers for psychopathology and abnormal movements during maintenance haloperidol treatment in male patients with schizophrenia,” Psychiatry Research, vol. 41, no. 3, pp. 191–202, 1992.
- S. Akhondzadeh, F. Rezaei, B. Larijani, A.-A. Nejatisafa, L. Kashani, and S. H. Abbasi, “Correlation between testosterone, gonadotropins and prolactin and severity of negative symptoms in male patients with chronic schizophrenia,” Schizophrenia Research, vol. 84, no. 2-3, pp. 405–410, 2006.
- P. Rinieris, M. Markianos, J. Hatzimanolis, and C. Stefanis, “A psychoendocrine study in male paranoid schizophrenics with delusional ideas of homosexual content,” Acta Psychiatrica Scandinavica, vol. 72, no. 3, pp. 309–314, 1985.
- E. C. Johnstone, T. J. Crow, and K. Mashiter, “Anterior pituitary hormone secretion in chronic schizophrenia: an approach to neurohumoral mechanisms,” Psychological Medicine, vol. 7, no. 2, pp. 223–228, 1977.
- J. E. Kleinman, D. R. Weinberger, and A. D. Rogol, “Plasma prolactin concentrations and psychopathology in chronic schizophrenia,” Archives of General Psychiatry, vol. 39, no. 6, pp. 655–657, 1982.
- J. G. Csernansky, E. Prosser, and J. Kaplan, “Possible associations among plasma prolactin levels, tardive dyskinesia, and paranoia in treated male schizophrenics,” Biological Psychiatry, vol. 21, no. 7, pp. 632–642, 1986.
- A. D. Prasad, “Concentration of prolactin in the plasma of schizophrenic patients with positive and negative symptoms,” Zhurnal Nevropatologii i Psikhiatrii Imeni S.S. Korsakova, vol. 86, no. 9, pp. 1400–1401, 1986 (Russian).
- D. J. Luchins, A. G. Robertson, and H. Y. Meltzer, “Serum prolactin, psychopathology, and ventricular size in chronic schizophrenia,” Psychiatry Research, vol. 12, no. 2, pp. 149–153, 1984.
- J. A. Cabranes, F. Fuentenebro, M. N. Recio, M. Borque, and M. I. Almoguera, “Prolactin secretion response to TRH stimulation in acute and chronic schizophrenic patients under neuroleptic treatment,” International Pharmacopsychiatry, vol. 17, no. 1, pp. 1–7, 1982.
- F. Brambilla, A. Guastalla, A. Guerrini et al., “Prolactin secretion in chronic schizophrenia,” Acta Psychiatrica Scandinavica, vol. 54, no. 4, pp. 275–286, 1976.
- D. Naber, M. Ackenheil, and G. Laakmann, “Basal and stimulated levels of prolactin, TSH, and LH in serum of chronic schizophrenic patients long-term treated with neuroleptics: relations to psychopathology,” Advances in Biochemical Psychopharmacology, vol. 24, pp. 419–423, 1980.
- J. H. Krystal, J. P. Seibyl, L. H. Price et al., “m-Chlorophenylpiperazine effects in neuroleptic-free schizophrenic patients: evidence implicating serotonergic systems in the positive symptoms of schizophrenia,” Archives of General Psychiatry, vol. 50, no. 8, pp. 624–635, 1993.
- M. Markianos, J. Hatzimanolis, L. Lykouras, and G. N. Christodoulou, “Prolactin responses to acute clomipramine and haloperidol of male schizophrenic patients in a drug-free state and after treatment with clozapine or with olanzapine,” Schizophrenia Research, vol. 56, no. 1-2, pp. 11–17, 2002.
- P. J. Cowen, H. Gadhvi, B. Gosden, and T. Kolakowska, “Responses of prolactin and growth hormone to L-tryptophan infusion: effects in normal subjects and schizophrenic patients receiving neuroleptics,” Psychopharmacology, vol. 86, no. 1-2, pp. 164–169, 1985.
- D. Nerozzi, A. Magnani, V. Sforza et al., “Prolactin and growth hormone responses to growth hormone-releasing hormone in acute schizophrenia,” Neuropsychobiology, vol. 23, no. 1, pp. 15–17, 1990.
- L. Cantalamessa, A. Catania, and A. Silva, “Gonadotropin releasing hormone elicits abnormal hormone responses in schizophrenia,” Psychoneuroendocrinology, vol. 10, no. 4, pp. 481–484, 1985.
- D. Nerozzi, A. Magnani, C. Dastoli et al., “Prolactin responses to domperidone in chronic schizophrenia,” Psychiatry Research, vol. 42, no. 2, pp. 159–169, 1992.
- L. J. Whalley, J. E. Christie, S. Brown, and G. W. Arbuthnott, “Schneider's first-rank symptoms of schizophrenia. An association with increased growth hormone response to apomorphine,” Archives of General Psychiatry, vol. 41, no. 11, pp. 1040–1043, 1984.
- T. Kolakowska, M. Gelder, and S. Fraser, “Neuroendocrine tests during treatment with neuroleptic drugs. III. Plasma growth hormone and prolactin responses to apomorphine,” British Journal of Psychiatry, vol. 139, no. 5, pp. 408–412, 1981.
- P. H. Gruen, E. J. Sachar, N. Altman, G. Langer, M. A. Tabrizi, and F. S. Halpern, “Relation of plasma prolactin to clinical response in schizophrenic patients,” Archives of General Psychiatry, vol. 35, no. 10, pp. 1222–1227, 1978.
- M. Markianos, G. Sakellariou, and E. Bistolaki, “Prolactin responses to haloperidol in drug-free and treated schizophrenic patients,” Journal of Neural Transmission—General Section, vol. 83, no. 1-2, pp. 37–42, 1991.
- X. Y. Zhang, D. F. Zhou, L. Y. Cao, P. Y. Zhang, G. Y. Wu, and Y. C. Shen, “Prolactin levels in male schizophrenic patients treated with risperidone and haloperidol: a double-blind and randomized study,” Psychopharmacology, vol. 178, no. 1, pp. 35–40, 2005.
- K. Otani, T. Kondo, S. Kaneko, M. Ishida, and Y. Fukushima, “Correlation between prolactin response and therapeutic effects of zotepine in schizophrenic patients,” International Clinical Psychopharmacology, vol. 9, no. 4, pp. 287–289, 1994.
- T. Kitamura, D. A. McGovern, N. W. Imlah, D. Wiles, and A. A. Schiff, “Plasma levels of fluphenazine and prolactin in psychiatric patients,” European Archives of Psychiatry and Neurological Sciences, vol. 237, no. 6, pp. 320–326, 1988.
- M. Larsson, R. Ohman, L. Wallin, J. Wålinder, and A. Carlsson, “Antipsychotic treatment with α-methyltyrosine in combination with thioridazine: prolactin response and interaction with dopaminergic precursor pools,” Journal of Neural Transmission—General Section, vol. 60, no. 2, pp. 115–132, 1984.
- J. C.-Y. Chou, R. Douyon, P. Czobor, J. Volavka, and T. B. Cooper, “Change in plasma prolactin and clinical response to haloperidol in schizophrenia and schizoaffective disorder,” Psychiatry Research, vol. 81, no. 1, pp. 51–55, 1998.
- P. Mohr, J. Horáček, L. Motlová, J. Libiger, and P. Czobor, “Prolactin response to D-fenfluramine challenge test as a predictor of treatment response to haloperidol in acute schizophrenia,” Schizophrenia Research, vol. 30, no. 1, pp. 91–99, 1998.
- J. A. Lieberman, J. M. Kane, A. Z. Safferman et al., “Predictors of response to clozapine,” Journal of Clinical Psychiatry, vol. 55, no. 9, pp. 126–128, 1994.
- H. Y. Meltzer and D. Busch, “Serum prolactin response to chlorpromazine and psychopathology in schizophrenics: implications for the dopamine hypothesis,” Psychiatry Research, vol. 9, no. 4, pp. 285–299, 1983.
- R. C. Smith, R. Baumgartner, C. H. Misra et al., “Haloperidol. Plasma levels and prolactin response as predictors of clinical improvement in schizophrenia: chemical v radioreceptor plasma level assays,” Archives of General Psychiatry, vol. 41, no. 11, pp. 1044–1049, 1984.
- W. M. Glazer, D. C. Moore, M. B. Bowers Jr., and W. A. Brown, “Serum prolactin and tardive dyskinesia,” The American Journal of Psychiatry, vol. 138, no. 11, pp. 1493–1496, 1981.
- G. M. Asnis, E. J. Sachar, and G. Langer, “Normal prolactin responses in tardive dyskinesia,” Psychopharmacology, vol. 66, no. 3, pp. 247–250, 1979.
- P. Ettigi, N. P. V. Nair, S. Lal, P. Cervantes, and H. Guyda, “Effect of apomorphine on growth hormone and prolactin secretion in schizophrenic patients, with or without oral dyskinesia, withdrawn from chronic neuroleptic therapy,” Journal of Neurology Neurosurgery and Psychiatry, vol. 39, no. 9, pp. 870–876, 1976.
- D. Viganò, P. Lissoni, F. Rovelli et al., “A study of light/dark rhythm of melatonin in relation to cortisol and prolactin secretion in schizophrenia,” Neuroendocrinology Letters, vol. 22, no. 2, pp. 137–141, 2001.
- M. L. Rao, G. Gross, B. Strebel et al., “Circadian rhythm of tryptophan, serotonin, melatonin, and pituitary hormones in schizophrenia,” Biological Psychiatry, vol. 35, no. 3, pp. 151–163, 1994.
- M. L. Rao, G. Gross, A. Halaris et al., “Hyperdopaminergia in schizophreniform psychosis: a chronobiological study,” Psychiatry Research, vol. 47, no. 2, pp. 187–203, 1993.
- D. Kemali, M. Maj, M. G. Ariano, F. Arena, and N. Lovero, “24-hour plasma levels of prolactin, cortisol, growth hormone and catecholamines in schizophrenic patients,” Neuropsychobiology, vol. 14, no. 3, pp. 109–114, 1985.
Copyright © 2014 Ravi Philip Rajkumar. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.